ArticleCell discovery2025
scCirclehunter delineates ecDNA-containing cells using single-cell ATAC-seq, with a focus on glioblastoma.
Article in Cell discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extrachromosomal DNA as a platform for epigenetic reprogramming in cancer.Molecular cancer · 2026Review
- Evolution of oncogene amplification across 86,000 cancer cell genomes.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
In cancer, extrachromosomal DNA (ecDNA) contributes to tumor heterogeneity and is associated with poor prognosis, but studies on patient-derived ecDNA are relatively limited at single-cell resolution. Here, we introduce scCirclehunter, a framework designed to identify ecDNA from scATAC-seq data and assign ecDNA to specific cell populations. Leveraging scCirclehunter and available glioblastoma (GBM) datasets, we uncover the inter-cellular heterogeneity of ecDNA-carrying cells across GBM patients and trace the trajectories of malignant cells within a single patient that harbors multiple ecDNAs. By integrating scRNA-seq data, we use ecNR2E1 as an example to demonstrate that ecDNA drives tumor progression in GBM through several mechanisms. Additionally, our findings suggest a potential link between ecDNA and increased mitochondrial transfer frequency. Overall, scCirclehunter provides a novel framework for analyzing patient-specific ecDNAs with single-cell precision, offering insights into the role of ecDNA-carrying cells in driving GBM heterogeneity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.